Location of Repository

LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN?

By V. B. Matveev, M. I. Volkova, D. Z. Kupchan and Ya. V. Gridneva

Abstract

<span>Eligard (leupropelin acetate, Atrigel delivery system) is a synthetic analogue of luteinizing-hormone-realizing hormone (LHRH), which causes a rapid reduction in the level of testosterone to the concentration comparable with that after surgical castration. Eligard demonstrated a considerable advantage over other LHRH analogues in the depth of androgenic suppression and in the frequency of transient increases in testosterone levels at the beginning and during therapy. Eligard is available as 1-, 3-, and 6-month depot formulations, which allows a flexible approach to be applied to individually making up a therapy regimen. Eligard is as effective as castration therapy techniques. Treatment with this drug shows the low frequency of side effects and is well tolerated by patients.</span

Topics: рак предстательной железы, агонисты ЛГРГ, Элигард, лейпрорелина ацетат, Medicine, R
Publisher: ABV-press
Year: 2010
OAI identifier: oai:doaj.org/article:7cfeb313e66e4dd78c63995b5d981e4c
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1996-1812 (external link)
  • https://doaj.org/toc/1726-9776 (external link)
  • http://oncourology.abvpress.ru... (external link)
  • https://doaj.org/article/7cfeb... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.